Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Premenopausal Women Clear all
Completed Not applicable Interventional Accepts healthy volunteers

CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women

NCT05336825
View directory record Official record
Conditions
Vulvodynia
Interventions
CO2 laser, Lidocaine patch 5%
Device · Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 3, 2026, 3:14 AM EDT
Terminated Not applicable Interventional

Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

NCT00794989
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
Ground Flaxseed, No Intervention
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women

NCT02683369
View directory record Official record
Conditions
Non-anemic Iron Deficiency
Interventions
Blood Builder®/Iron Response®
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women

NCT00352157
View directory record Official record
Conditions
Skin Aging, Weight Loss
Interventions
Revival Soy Dietary Supplement
Behavioral
Lead sponsor
Physicians Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00996164
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 3, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 3, 2026, 3:14 AM EDT
Recruiting No phase listed Observational

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

NCT01788839
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Interventions
surveys, Blood draw, Transvaginal ultrasounds
Behavioral · Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 3, 2026, 3:14 AM EDT
Recruiting Phase 2 Interventional

Uterine Preservation Via Lifestyle Transformation

NCT05903131
View directory record Official record
Conditions
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Interventions
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Albuquerque, New Mexico • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

NCT01728454
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 3, 2026, 3:14 AM EDT
Completed No phase listed Observational

A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy

NCT00644683
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 3, 2026, 3:14 AM EDT
Recruiting No phase listed Observational

The Immune System's Response to Young Women's Breast Cancer

NCT01503190
View directory record Official record
Conditions
Breast Cancer, Breast Cancer and Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 3, 2026, 3:14 AM EDT
Completed No phase listed Observational

Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

NCT00005605
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Denosumab
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Creatine Supplementation and Resistance Training in Premenopausal Females

NCT05745870
View directory record Official record
Conditions
Health Behavior
Interventions
Creatine Monohydrate Supplementation
Dietary Supplement
Lead sponsor
University of Idaho
Other
Eligibility
18 Years to 22 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Moscow, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2Phase 3 Interventional

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

NCT00189124
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Dehydroepiandrosterone (DHEA)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

NCT04978688
View directory record Official record
Conditions
Healthy
Interventions
Relugolix, E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk

NCT01559194
View directory record Official record
Conditions
Breast Cancer, Weight Loss
Interventions
Low Fat Diet plus exercise, Low Carbohydrate diet + Exercise
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

Raloxifene in Preventing Breast Cancer in Premenopausal Women

NCT00019500
View directory record Official record
Conditions
Breast Cancer
Interventions
raloxifene, evaluation of cancer risk factors
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
23 Years to 47 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

NCT03396315
View directory record Official record
Conditions
IOP, Osteoporosis
Interventions
Alendronate, Zoledronic Acid
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

NCT01440803
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Teriparatide, Saline Placebo
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 3, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation

NCT01778712
View directory record Official record
Conditions
Menopause, Visceral Adipose Tissue Accumulation, Abdominal Obesity, Obesity, Overweight
Interventions
Multi-level intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
42 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 3, 2026, 3:14 AM EDT
Active, not recruiting Phase 2 Interventional

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 3, 2026, 3:14 AM EDT